trending Market Intelligence /marketintelligence/en/news-insights/trending/q7-VcLxk2_EV_ObVkRi2RA2 content esgSubNav
In This List

Rhizen drug receives US FDA's orphan drug designation

Blog

Insight Weekly: Banks brace for recession; Europe PE deal values soar; US solar imports rebound

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook


Rhizen drug receives US FDA's orphan drug designation

Alembic Pharmaceuticals Ltd. said its associate company Rhizen Pharmaceuticals SA received the U.S. Food and Drug Administration's orphan drug designation for tenalisib.

Tenalisib, also known as RP6530, is a highly selective and orally active dual PI3K delta/gamma inhibitor used for the treatment of peripheral T-cell lymphoma, a type of blood cancer.

The treatment was previously granted the fast track designation by the FDA.